Lysine-specific Demethylase 1 (lsd1) Is a Biomarker for Breast Cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses that lysine-specific demethylase 1 (LSD1) serves as a novel biomarker for breast cancer, particularly useful for diagnosing breast cancer and determining its prognosis. The invention describes methods for measuring LSD1 expression in tissue samples and establishes that higher LSD1 levels indicate aggressive cancer, especially in hormone receptor–negative cases. Furthermore, it reveals that inhibiting LSD1, including with certain monoamine oxidase (MAO) inhibitors, can arrest the growth of cancer cells (breast, lung carcinoma, and sarcoma), suggesting new therapeutic options.

Use CasesContent extracted from patent full text and abstract with AI.

• Early and accurate diagnosis of breast cancer by measuring LSD1 expression.
• Determination of breast cancer aggressiveness to inform prognosis and personalized treatment planning.
• Screening and monitoring of patients at risk or under treatment for breast cancer.
• Development of new therapies targeting LSD1 for treating breast cancer, lung carcinoma, and various sarcomas.
• Use of existing MAO inhibitors as potential treatments for cancers with high LSD1 expression.
• Companion diagnostic tests to identify patients likely to benefit from LSD1-targeted therapies.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables more precise and earlier diagnosis of breast cancer, improving patient outcomes.
• Helps distinguish aggressive from less aggressive tumors, allowing for tailored therapies.
• Provides a new therapeutic target—LSD1—in cancers lacking effective treatments, especially hormone receptor–negative breast cancers.
• Repurposes existing drugs (MAO inhibitors) with known safety profiles, potentially accelerating clinical application.
• Facilitates non-invasive or minimally invasive diagnostic procedures using tissue biopsies and ELISA assays.
• Improves stratification of patients for clinical trials and therapy selection, optimizing treatment effectiveness.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to novel biomarker for breast cancer, namely LSD1 and its application in inter alia the diagnosis of breast cancer. Furthermore, the present invention discloses a method of determining the LSD1 protein amount and the effect of LSD1 inhibitors on cancer cells selected from breast cancer, lung carcinoma and sarcoma.